Printed From BioPortfolio.com

Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal

02:52 EST 8 Nov 2017 | ChinaBio Today

Zhejiang Huahai Pharma acquired Greater China rights to EU-101, a preclinical immuno-oncology candidate discovered by Eutilex of South Korea, in a $65 million agreement. Huahai made a $30 million equity investment into Eutilex, and it will pay up to $35 million in milestones on 10 immuno-oncology indications. Eutilex will also receive royalties on China sales. In an unusual provision, Huahai will gain from Eutilex's out-licensing revenues of EU-101, and it will receive royalties on ex-China sales. More details....

Share this with colleagues:

Original Article: Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal

More From BioPortfolio on "Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Cancer
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches